Biohaven Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Public

  • Employees
  • 274

Employees

  • Stock Symbol
  • BHVN

Stock Symbol

  • Investments
  • 9

  • Share Price
  • $12.39
  • (As of Friday Closing)

Biohaven General Information

Description

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.

Contact Information

Formerly Known As
Biohaven Research
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 215 Church Street
  • New Haven, CT 06510
  • United States
+1 (203)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NYS
Vertical(s)
Corporate Office
  • 215 Church Street
  • New Haven, CT 06510
  • United States
+1 (203)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Biohaven Stock Performance

As of 20-Nov-2026, Biohaven’s stock price is $12.39. Its current market cap is $1.87B with 151M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$12.39 $13.65 $8.03 - $18.24 $1.87B 151M 3.22M -$3.86

Biohaven Financials Summary

As of 30-Sep-2026, Biohaven has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 2,045,603 1,552,012 3,427,088 3,224,971
Revenue 0 0 0 0
EBITDA (532,305) (727,458) (837,832) (402,639)
Net Income (542,677) (738,822) (846,422) (408,168)
Total Assets 263,676 451,447 615,107 513,212
Total Debt 300,444 284,614 36,584 30,877
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Biohaven Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Biohaven‘s full profile, request access.

Request a free trial

Biohaven Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization
Drug Discovery
New Haven, CT
274 As of 2025

New York, NY
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Biohaven Competitors (30)

One of Biohaven’s 30 competitors is Neurogene, a Formerly VC-backed company based in New York, NY.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Neurogene Formerly VC-backed New York, NY
Alector Formerly VC-backed South San Francisco, CA
Design Therapeutics Formerly VC-backed Carlsbad, CA
CuraSen Venture Capital-Backed San Carlos, CA
Denali Therapeutics Formerly VC-backed South San Francisco, CA
You’re viewing 5 of 30 competitors. Get the full list »

Biohaven Patents

Biohaven Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260224727-A1 Compounds and methods for treating, ameliorating, or preventing arthritis Pending 31-Jan-2023
WO-2022251752-A2 Dual treatment of migraine Inactive 25-May-2021
WO-2022251752-A3 Dual treatment of migraine Inactive 25-May-2021
WO-2022165291-A1 Pharmaceutical compositions of cgrp inhibitors and methods of their use Inactive 01-Feb-2021
WO-2022132989-A1 Compositions for improved delivery of cgrp inhibitors Inactive 17-Dec-2020 C07K14/57527
To view Biohaven’s complete patent history, request access »

Biohaven Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Biohaven Investments & Acquisitions (9)

Biohaven’s most recent deal was a Merger/Acquisition with Pyramid Biosciences for . The deal was made on 07-Jan-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Pyramid Biosciences 07-Jan-2024 Merger/Acquisition Drug Discovery
PIPr Therapeutics 10-Mar-2023 Later Stage VC Drug Discovery
Channel Biosciences 01-Apr-2022 Merger/Acquisition Diagnostic Equipment
Knopp Biosciences 01-Apr-2022 Merger/Acquisition Drug Discovery
Kleo Pharmaceuticals 04-Jan-2021 Merger/Acquisition Drug Discovery
You’re viewing 5 of 9 investments and acquisitions. Get the full list »

Biohaven ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

33.99 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Biohaven’s complete esg history, request access »

Biohaven FAQs

  • When was Biohaven founded?

    Biohaven was founded in 2013.

  • Where is Biohaven headquartered?

    Biohaven is headquartered in New Haven, CT.

  • What is the size of Biohaven?

    Biohaven has 274 total employees.

  • What industry is Biohaven in?

    Biohaven’s primary industry is Drug Discovery.

  • Is Biohaven a private or public company?

    Biohaven is a Public company.

  • What is Biohaven’s stock symbol?

    The ticker symbol for Biohaven is BHVN.

  • What is the current stock price of Biohaven?

    As of 20-Nov-2026 the stock price of Biohaven is $12.39.

  • What is the current market cap of Biohaven?

    The current market capitalization of Biohaven is $1.87B.

  • Who are Biohaven’s competitors?

    Neurogene, Alector, Design Therapeutics, CuraSen, and Denali Therapeutics are some of the 30 competitors of Biohaven.

  • What is Biohaven’s annual earnings per share (EPS)?

    Biohaven’s EPS for 12 months was -$3.86.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process